SCHEMBL1920776

SCHEMBL1920776

COc1ccccc1Nc1ccc(-c2ccc(Nc3ccccc3OC)cc2)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.73
ALDH1A1 P00352 5/20 0.73
MAPK1 P28482 3/20 0.73
L3MBTL1 Q9Y468 2/20 0.73
GAA P10253 4/20 0.56
RAB9A P51151 3/20 0.56
NPC1 O15118 2/20 0.56
MAPK10 P53779 2/20 0.51
MAPK8 P45983 1/20 0.51
MAPK14 Q16539 1/20 0.51
KMT2A Q03164 4/20 0.50
KDM4E B2RXH2 3/20 0.50
MEN1 O00255 3/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
AURKA O14965 1/20 0.49
POLB P06746 2/20 0.49
HTT P42858 2/20 0.47
THRB P10828 1/20 0.47
RECQL P46063 1/20 0.47
MMP14 P50281 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5923796 0.94 MAPT (0.81) MAPTALDH1A1MAPK1L3MBTL1GAA
SCHEMBL29744518 0.88 MAPT (0.72) MAPTALDH1A1MAPK1L3MBTL1GAA
SCHEMBL2095055 0.88 MAPT (0.72) MAPTALDH1A1MAPK1L3MBTL1GAA
SCHEMBL10480096 0.86 MAPT (0.71) MAPTALDH1A1MAPK1L3MBTL1GAA
SCHEMBL17201829 0.86 MAPT (0.71) MAPTALDH1A1MAPK1L3MBTL1GAA
SCHEMBL30741238 0.86 MAPT (0.71) MAPTALDH1A1MAPK1L3MBTL1GAA
SCHEMBL15883217 0.86 ALDH1A1 (0.71) MAPTALDH1A1MAPK1L3MBTL1GAA
SCHEMBL17549434 0.86 MAPT (0.56) MAPTALDH1A1MAPK1L3MBTL1GAA
Hydrochloric Acid SCHEMBL7128944 0.86 MAPT (0.70) MAPTALDH1A1MAPK1L3MBTL1GAA
SCHEMBL1618638 0.85 MAPT (1.00) MAPTALDH1A1MAPK1L3MBTL1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9684253-B2 Triphenylamine derivative, electrophotographic photosensitive member, and image forming apparatus KYOCERA DOCUMENT SOLUTIONS INC. (JP) 2017-06-20 US disclosed
US-20160062254-A1 TRIPHENYLAMINE DERIVATIVE, ELECTROPHOTOGRAPHIC PHOTOSENSITIVE MEMBER, AND IMAGE FORMING APPARATUS KYOCERA DOCUMENT SOLUTIONS INC. (JP) 2016-03-03 US disclosed
EP-1528074-B1 NOVEL TRIARYLAMINE POLYMER, PROCESS FOR PRODUCING THE SAME, AND USE THEREOF TOSOH CORP (JP) 2014-03-26 EP disclosed
EP-2327739-A1 Novel triarylamine polymer, process for its production and its use TOSOH CORPORATION (JP) 2011-06-01 EP disclosed
US-7608680-B2 Triarylamine polymer, process for producing the same, and use thereof TOSOH CORPORATION (JP) 2009-10-27 US disclosed
US-20060241278-A1 Novel triarylamine polymer, process for producing the same, and use thereof TOSOH CORPORATION (JP) 2006-10-26 US disclosed
US-20060017040-A9 Novel triarylamine polymer, process for producing the same, and use thereof SUZUKI TAKAO 2006-01-26 US disclosed
EP-1528074-A1 NOVEL TRIARYLAMINE POLYMER, PROCESS FOR PRODUCING THE SAME, AND USE THEREOF Tosoh Corporation (JP) 2005-05-04 EP disclosed
US-20040262574-A1 Novel triarylamine polymer, process for producing the same, and use thereof TOSOH CORPORATION (JP) 2004-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160062254-A1 TRIPHENYLAMINE DERIVATIVE, ELECTROPHOTOGRAPHIC PHOTOSENSITIVE MEMBER, AND IMAGE FORMING APPARATUS IK, NAT1, TPT1 MAPT 3738/4885ALDH1A1 553/4885MAPK1 1318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.